For a novel immunotherapy for late-stage lung cancer to get to patients, the pharmaceutical company behind the treatment needed to overcome obstacles despite being approved by the FDA. Dig into how they did it in our #CaseStudy: https://bit.ly/3QKI4d3
Point B’s Post
More Relevant Posts
-
Theralase Technologies (TSXV: TLT) Inc (OTCQB:TLTFF) CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17 million, crucial for advancing its Phase II clinical study targeting non-muscle invasive bladder cancer, particularly Bacillus Calmette-Guérin (BCG)-Unresponsive cases. The study's data shows promising superiority over FDA-approved drugs from major pharmaceutical companies, making it a groundbreaking development for Theralase. DuMoulin-White detailed the unique approach, utilizing a drug-device combination involving a light-sensitive drug instilled into the bladder. This innovative method selectively targets cancer cells, minimizing damage to healthy cells, a departure from traditional pharmacological approaches. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/yx5S1054pFO
Theralase makes positive progress on Phase II study on bladder cancer; targets BTD with FDA
proactiveinvestors.com
To view or add a comment, sign in
-
PERI is a not-for-profit organization that has been educating the pharmaceutical industry since 1989.
The next session of PERI's virtual "Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development" program will be here before you know it. Scheduled for October 11 - 13, this course features 10 experts in the field of #oncology, including several professionals from FDA and NCI. Register now at discounted early rates, but for a limited time only: https://lnkd.in/g-MqimUT
Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development - Peri.org
https://peri.org
To view or add a comment, sign in
-
Japan Approves Vyloy for Gastric Cancer: A New Era in Targeted Therapy Astellas has received regulatory approval for its claudin 18.2 (CLDN18.2) targeted therapy, Vyloy, as a treatment for gastric cancer in Japan. The approval is significant in addressing the lack of therapeutic innovation in gastric cancer and offers hope to patients. While Astellas faced a setback in the US when the FDA declined its marketing application for the therapy, the approval in Japan demonstrates the importance of adhering to quality control measures. Vyloy specifically targets the CLDN18.2 biomarker and represents a new era of targeted therapy for gastric cancer. The approval paves the way for further research and development in this field and highlights the power of collaboration in driving innovation and improving patient care. For more details please click the link! https://lnkd.in/d4wTXz8j #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
Japan Approves Vyloy for Gastric Cancer: A New Era in Targeted Therapy
https://marketaccesstoday.com
To view or add a comment, sign in
-
What are the latest developments in lung cancer? Join Bloomberg virtually on June 12 for an overview of the current treatments available for lung cancer patients, including the loss of market exclusivity for key products in the space. We will also break down the latest developments as the pharmaceutical industry targets earlier stage patients with new drugs and combinations. Register here: https://bloom.bg/3KYVYoJ #pharma #corporations #biotech #lung #cancer #oncology
To view or add a comment, sign in
-
-
October is #BreastCancerAwarenessMonth. Breast Cancer Awareness Month is a critical time for our organization. NeoGenomics is passionate about equipping physicians and pharmaceutical partners with the tools to deliver precision medicine to their patients. This includes national statistics as well as specific insights derived specifically from NeoGenomics. #BreastCancer #FastFacts #NeoGenomics #CancerTesting
To view or add a comment, sign in
-
-
Zai Lab's partners Pfizer and Genmab jointly announced that the US FDA has approved their supplementary Biologics License Application (sBLA) for TIVDAK(®). This sets the stage for its use in the treatment of patients who are suffering from recurrent or metastatic cervical cancer, whose condition has progressed during or after chemotherapy. There's a considerable unmet need for cervical cancer treatment. The disease - recurrent and/or metastatic cervical cancer - is extremely destructive and often incurable; statistics show that up to 15% of adult cervical cancer patients experience metastasis at diagnosis, and for those diagnosed early and treated, as many as 61%(v) suffer recurrences. #QMportfolio #QMhealthcare #ZaiLab #Pfizer #Genmab #FDA #TIVDAKApproval #CervicalCancerTreatment
To view or add a comment, sign in
-
-
#ESMO23: #BMS presented efficacy results of the CheckMate-77T trial, demonstrating the efficacy of #Opdivo as neoadjuvant therapy in #NSCLC #patients https://lnkd.in/gpKjGB6X #pharma #pharmaceutical #Science #news #media #medicine #Europe #Cancer #Oncology #ESMO #ESMO2023
European Society for Medical Oncology (ESMO) Congress 2023 | News | Updates | iPharmaCenter
ipharmacenter.com
To view or add a comment, sign in
-
ASCO GU 2024 Highlights - clear progress in the genitourinary cancer space but key questions remain. Read more from our experts or DM for further details Non-metastatic prostate cancer: - With active surveillance being recommended for low-risk PCa, are there opportunities for any systemic treatment? - Can NHTs secure approvals for localized disease? Metastatic prostate cancer: - While triplet regimens (NHT chemo ADT) are approved in mHSPC, are patients willing to tolerate chemo-toxicities? - Can anti-PSMA RLTs expand to earlier lines? Even if approved, will they be widely accessible? - Can other PSMA-targeting modalities (ADC, bsAb & CARTs) replicate the efficacy of RLTs? - What is the exact role of the current PARPi? - Is there any hope for anti-PD-(L)1s, following the failure of several large Ph 3 trials? What are the prospects of CONTACT-02 (anti-PD-L1 TKI)? Bladder cancer: NMIBC - With the increasing use of bladder-preserving treatments, what are the future options available before and after BCG treatments? - Can localized intravesical therapies replace BCG? MIBC: - What is the role of ICP (immune checkpoint) inhibitors in a perioperative MIBC setting? mUC - What is the role of biomarker-targeted therapies and how will they be sequenced vs. PD(L)1 in light of recent FDA actions? RCC - Role of SC vs. IV PD-1s? Will higher ADA impact the higher convenience offered by SC? - While recent PD-1 data showed OS benefit adjuvant ccRCC, why did previous PD-(L)1 trials fail?
📢 Explore the future of oncology with our latest white paper 📰 , delving into groundbreaking research, innovative therapies, and the evolving landscape of cancer treatment. To gain valuable insights and stay ahead in the rapidly advancing field of oncology, visit our website🌐https://lnkd.in/gmGzA86H for more information. #Oncology #CancerResearch #InnovationInHealthcare #WhitePaper #GU24 #asco #conference #pharmanews #pharmaceutical #healthcare #pharmaceuticalindustry #ASCOGU24 #MedicalConference
To view or add a comment, sign in
-
-
Trial costs can cascade due to even the most common hurdles. According to the NIH, a phase III study could have up to 120 protocol deviations. With an average cost between $25,000 - $55,000 per deviation, reducing deviations can have both fiscal rewards and a strong impact on the efficacy of your study. Learn how Longboat reduced deviations by over 20% in a Phase III breast cancer trial across 188 trial sites.
Reduce Protocol Deviations with Longboat
info.advarra.com
To view or add a comment, sign in
-
Trial costs can cascade due to even the most common hurdles. According to the NIH, a phase III study could have up to 120 protocol deviations. With an average cost between $25,000 - $55,000 per deviation, reducing deviations can have both fiscal rewards and a strong impact on the efficacy of your study. Learn how Longboat reduced deviations by over 20% in a Phase III breast cancer trial across 188 trial sites.
Reduce Protocol Deviations with Longboat
info.advarra.com
To view or add a comment, sign in